Clinical Trial Update: Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating mesenchymal stem cells to fill bone void defects in patients with benign bone lesions has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Emory University | Conditions: Bone Neoplasms | Phase 2, Phase 3 | Status: WITHDRAWN